Elanco Q1 revenue $1.225B, adj. EPS $0.36; FY22 guidance lowered on FX headwind of $140M

Elanco Animal Health Inc

2022-Q1 EPS reported $0.10 revenue$1,225,000,000

Q1 revenue $1,225M (-1% reported, +2% CER); reported net income $48M vs -$61M; adjusted EPS $0.36 vs $0.37.
FY22 revenue guidance cut to $4,700-4,755M from $4,745-4,800M due to incremental $45M FX headwind; adj. EPS guidance $1.15-1.21.
Strategic alliance with Royal DSM for exclusive U.S. rights to Bovaer methane-reducing feed additive; >$200M annual revenue potential.
Pet Health revenue $639M; Seresto grew 6% to $161M; Advantage declined 5% to $137M, with temporary U.S. stock-outs.
Completed $406M tender on 4.272% Senior Notes due 2023; new $250M term facility with Farm Credit; net leverage 5.6x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.